Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Blood Cancer Journal (7)
Leukemia (3)
Nature Medicine (1)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (6)
Correspondence (4)
Amendments and Corrections (1)

Subject Check one or more subjects to show results from those subjects only.

Cancer
Diseases
Drug discovery
Health care
Medical research

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–11 of 11 results

Advanced filters: Author: Maro Ohanian Clear advanced filters

Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia

Courtney D. DiNardo
Wei-Ying Jen
Hagop M. Kantarjian
Amendments and Corrections10 Dec 2025
Leukemia

Volume: 40, P: 262
Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype

Bachar Samra
Guillaume Richard-Carpentier
Nicholas J. Short
ResearchOpen Access04 May 2020
Blood Cancer Journal

Volume: 10, P: 1-9
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

A mitochondrial complex I inhibitor exhibited dose-limiting toxicities, including neurotoxicity, in patients with acute myeloid leukemia and solid tumors, warranting further studies to evaluate the mechanism linking oxidative phosphorylation inhibition and neurotoxicity.

Timothy A. Yap
Naval Daver
Marina Konopleva
Research19 Jan 2023
Nature Medicine

Volume: 29, P: 115-126
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia

Courtney D. DiNardo
Wei-Ying Jen
Hagop M. Kantarjian
Research25 Feb 2025
Leukemia

Volume: 39, P: 854-863
VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial

Mahesh Swaminathan
Courtney D. DiNardo
Marina Y. Konopleva
CorrespondenceOpen Access02 Apr 2025
Blood Cancer Journal

Volume: 15, P: 1-4
Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML

Musa Yilmaz
Hagop Kantarjian
Naval Daver
ResearchOpen Access02 May 2022
Blood Cancer Journal

Volume: 12, P: 1-9
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy

Sangeetha Venugopal
Koichi Takahashi
Courtney D. DiNardo
ResearchOpen Access25 Jan 2022
Blood Cancer Journal

Volume: 12, P: 1-7
Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality

Ghayas C. Issa
Hagop M. Kantarjian
Jorge E. Cortes
Research16 Jun 2020
Leukemia

Volume: 34, P: 2914-2924
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents

Danielle Hammond
Sanam Loghavi
Courtney D. DiNardo
CorrespondenceOpen Access21 Sept 2023
Blood Cancer Journal

Volume: 13, P: 1-4
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

Abhishek Maiti
Courtney D. DiNardo
Marina Y. Konopleva
CorrespondenceOpen Access01 Feb 2021
Blood Cancer Journal

Volume: 11, P: 1-6
Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study

Patrick K. Reville
Hagop M. Kantarjian
Tapan M. Kadia
CorrespondenceOpen Access17 Mar 2021
Blood Cancer Journal

Volume: 11, P: 1-5

Search

Search articles by subject, keyword or author

Show results from

Advanced search

Quick links

Explore articles by subject
Find a job
Guide to authors
Editorial policies

Nature.com

nature.com sitemap

About Nature Portfolio

About us
Press releases
Press office
Contact us

Discover content

Journals A-Z
Articles by subject
protocols.io
Nature Index

Publishing policies

Nature portfolio policies
Open access

Author & Researcher services

Reprints & permissions
Research data
Language editing
Scientific editing
Nature Masterclasses
Research Solutions

Libraries & institutions

Librarian service & tools
Librarian portal
Open research
Recommend to library

Advertising & partnerships

Advertising
Partnerships & Services
Media kits
Branded content

Professional development

Nature Awards
Nature Careers
Nature Conferences

Regional websites

Nature Africa
Nature China
Nature India
Nature Japan
Nature Middle East

Privacy Policy
Use of cookies
Legal notice
Accessibility statement
Terms & Conditions
Your US state privacy rights

Search

Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia

Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia

VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy

Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality

Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study

Search

Quick links